Michael M. Gottesman

National Institutes of Health — United States

Medicine · Health Sciences

107h-index64.8kcitations698works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(303), RNA Interference and Gene Delivery(83), Cancer therapeutics and mechanisms(73), HIV/AIDS drug development and treatment(58), Epigenetics and DNA Methylation(49)

Publications698 total

Abstract A043: P-gp overexpression confers resistance to treatment with the antibody-drug conjugate mirvetuximab soravtansine
Molecular Cancer Therapeutics·2025
Editor’s Note: <i>MDR1</i> Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer
Cancer Research·2025Open Access
Abcb5-deficient mice show a subtle, pleiotropic phenotype indicating a role for this transporter in intermediary metabolism
iScience·2025Open Access
Resistance signatures manifested in early drug response across cancer types and species
Cancer Drug Resistance·2025Open Access
Angulin-1/LSR inhibition transiently disrupts the blood-tumor barrier to enhance doxil permeability and impair malignant glioma progression
2025· 1 citedOpen Access
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma
Nature Communications·2025· 1 citedOpen Access
Functional Implications of the Conformational Landscape of a Multidrug Transporter Revealed by Structures of Zebrafish Abcb4
2025Open Access
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters
2025· 2 citedOpen Access
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter <i>SLC43A1</i> (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells
2025Open Access
Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2025Open Access
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
iScience·2025· 2 citedOpen Access
Correction: Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood–brain barrier
Fluids and Barriers of the CNS·2025Open Access
EXTH-22. TARGETING MITOCHONDRIAL PROTEASE IN DIFFUSE GLIOMAS
Neuro-Oncology·2024Open Access
Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2024Open Access
Figure 5 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2024Open Access
page 1 of 35Next →

Frequent Co-authors

Ira Pastan(25), Suresh V. Ambudkar(10), Kazumitsu Ueda(9), Matthew D. Hall(7), Igor B. Roninson(6), Antonio Tito Fojo(6), Carol Cardarelli(5), I Pastan(4), Chava Kimchi‐Sarfaty(4), Zuben E. Sauna(4), Marilyn M. Cornwell(4), Susan E. Bates(3), Mark C. Willingham(3), Anna Maria Calcagno(3), Saibal Dey(3), Murali Ramachandra(3), Janice E. Chin(3), Douglas P. Clark(3), Donglai Shen(3), Jean-Pierre Gillet(3)